OPIANT PHARMACEUTI COM USD0.001 (OPNT)

23.05
0.95 3.96
OTC
Prev Close 24.00
Open 23.25
Day Low/High 22.00 / 23.90
52 Wk Low/High 5.00 / 25.38
Volume 9.90K
Exchange OTC
Shares Outstanding 2.03B
Market Cap 48.64M
Div & Yield N.A. (N.A)

Latest News

Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization

Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization

Company Received Additional Payment From SWK Funding LLC Based on Achievement of $25 Million Net Sales of NARCAN® Nasal Spray Milestone

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For New NARCAN® Nasal Spray Patent

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For New NARCAN® Nasal Spray Patent

Listing Strengthens IP Position and Enhances NARCAN Product Exclusivity

Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions

Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions

Overdoses kill 91 people a day.

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For New NARCAN® Nasal Spray Patent

Listing Bolsters IP Estate and Enhances NARCAN Product Exclusivity

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings For Two New NARCAN® Nasal Spray Patents

Listings Significantly Strengthen IP Estate and Enhance NARCAN Product Exclusivity

Opiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development Of OPNT002 For The Treatment Of Alcohol Use Disorder

Company Plans Additional Clinical Trials This Year; Topline Data Expected in 2018

Opiant Pharmaceuticals, Inc. Announces Establishment Of Audit, Compensation And Nominating And Corporate Governance Committees

Company to pursue up-listing to a major stock exchange in 2017

Opiant Pharmaceuticals, Inc. Announces FDA Approval Of 2mg Formulation Of NARCAN (naloxone HCI) Nasal Spray

Opiant Pharmaceuticals, Inc. Announces FDA Approval Of 2mg Formulation Of NARCAN (naloxone HCI) Nasal Spray

2mg Formulation Indicated for Patients At-Risk for Severe Opioid Withdrawal

Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization

Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization

SWK to Acquire Certain NARCAN® Royalties For Up to $17.5 Million

Opiant Pharmaceuticals, Inc. Announces Appointment Of Thomas T. Thomas To Board Of Directors

Opiant Pharmaceuticals, Inc. Announces Appointment Of Thomas T. Thomas To Board Of Directors

Thomas Brings Global Pharmaceutical and Financial Expertise to Opiant's Board

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For Narcan® Nasal Spray Patent

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For Narcan® Nasal Spray Patent

Listing Offers Product Exclusivity Until 2035